News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Learning from Iceland’s Model for Genetic Research
Catherine Offord | Jun 1, 2017
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
Former Head of Genzyme Dies
Diana Kwon | May 15, 2017
Henri Termeer helped usher the biotech company into an industry behemoth.
Life Science Leaders Meet at White House
Kerry Grens | May 8, 2017
Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.
Opinion: Preparing for Potential Disasters
Larissa Paschyn | Jan 25, 2017
How to increase the resiliency of biotechnology organizations in the face of emergency risks
Monsanto and Bayer Announce Approval of Massive Merger
Bob Grant | Dec 13, 2016
On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.
Oligonucleotide Therapeutics Near Approval
Catherine Offord | Dec 1, 2016
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.
Another CRISPR Biotech Goes Public
Bob Grant | Sep 12, 2016
CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.
That Other CRISPR Patent Dispute
Kerry Grens | Aug 31, 2016
The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.
Opinion: How to Avoid Legal Problems in Collaborative Research
Catherine Coombes | Aug 31, 2016
A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.
Theranos CEO Presents New Device
Kerry Grens | Aug 2, 2016
The troubled firm’s medical conference appearance didn’t deliver the evidence many hoped for.